Watanabe Jun, Miki Atsushi, Sakuma Yasunaru, Shimodaira Kentaro, Aoki Yuichi, Meguro Yoshiyuki, Morishima Kazue, Endo Kazuhiro, Sasanuma Hideki, Lefor Alan Kawarai, Teratani Takumi, Fukushima Noriyoshi, Kitayama Joji, Sata Naohiro
Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Shimotsuke 329-0498, Japan.
Department of Pathology, Jichi Medical University, Shimotsuke 329-0498, Japan.
Cancers (Basel). 2022 Apr 28;14(9):2213. doi: 10.3390/cancers14092213.
Background: Osteopenia is defined as low bone mineral density (BMD) and has been shown to be associated with outcomes of patients with various cancers. The association between osteopenia and perihilar cholangiocarcinoma is unknown. The aim of this study was to evaluate osteopenia as a prognostic factor in patients with perihilar cholangiocarcinoma. Methods: A total of 58 patients who underwent surgery for perihilar cholangiocarcinoma were retrospectively analyzed. The BMD at the 11th thoracic vertebra was measured using computed tomography scan within one month of surgery. Patients with a BMD < 160 HU were considered to have osteopenia and b BMD ≥ 160 did not have osteopenia. The log-rank test was performed for survival using the Kaplan−Meier method. After adjusting for confounding factors, overall survival was assessed by Cox′s proportional-hazards model. Results: The osteopenia group had 27 (47%) more females than the non-osteopenia group (p = 0.036). Median survival in the osteopenia group was 37 months and in the non-osteopenia group was 61 months (p = 0.034). In multivariable analysis, osteopenia was a significant independent risk factor associated with overall survival in patients with perihilar cholangiocarcinoma (hazard ratio 3.54, 95% confidence interval 1.09−11.54, p = 0.036), along with primary tumor stage. Conclusions: Osteopenia is associated with significantly shorter survival in patients with perihilar cholangiocarcinoma.
骨质减少被定义为低骨矿物质密度(BMD),并且已被证明与各种癌症患者的预后相关。骨质减少与肝门部胆管癌之间的关联尚不清楚。本研究的目的是评估骨质减少作为肝门部胆管癌患者的一个预后因素。方法:对总共58例行肝门部胆管癌手术的患者进行回顾性分析。在术后1个月内使用计算机断层扫描测量第11胸椎的骨密度。骨密度<160 HU的患者被认为有骨质减少,而骨密度≥160的患者则没有骨质减少。使用Kaplan-Meier方法进行生存的对数秩检验。在调整混杂因素后,通过Cox比例风险模型评估总生存期。结果:骨质减少组女性比非骨质减少组多27例(47%)(p = 0.036)。骨质减少组的中位生存期为37个月,非骨质减少组为61个月(p = 0.034)。在多变量分析中,骨质减少是与肝门部胆管癌患者总生存期相关的一个显著独立危险因素(风险比3.54,95%置信区间1.09 - 11.54,p = 0.036),与原发肿瘤分期一样。结论:骨质减少与肝门部胆管癌患者的生存期显著缩短相关。